antineoplaston A10

Phase 2Small molecule

BBurzynski Research Institute

antineoplaston A10 is one of 827 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

826

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

EpendymomaActive, not recruiting

AstrocytomaActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

ParagangliomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

Central Nervous System CancerActive, not recruiting

Mixed GliomaActive, not recruiting

Kidney CancerActive, not recruiting

GliomaPhase 2

Active, not recruiting

EpendymomaPhase 2

Active, not recruiting

AstrocytomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaPhase 2

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Central Nervous System CancerPhase 2

Active, not recruiting

Mixed GliomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Showing 10 of 43 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

antineoplaston A10

BBurzynski Research Institute

Phase 2

3 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioma4 trials

Antineoplaston Therapy in Treating Patients With Brain Stem Glioma

Completed·—·Phase 2·NCT00003459·40 enrolled

Antineoplaston Therapy in Treating Children With Visual Pathway Glioma

Completed·—·Phase 2·NCT00003477·12 enrolled

A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

Suspended·—·Phase 2·NCT02742883·1 enrolled

Show 1 more trial

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Terminated·—·Phase 2·NCT00003535·9 enrolled

Lymphoma4 trials

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

Terminated·—·Phase 2·NCT00003501·2 enrolled

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Terminated·—·Phase 2·NCT00003498·5 enrolled

Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

Terminated·—·Phase 2·NCT00003500·12 enrolled

Show 1 more trial

Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00003499·31 enrolled

Lung Cancer4 trials

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

Terminated·—·Phase 2·NCT00003495·7 enrolled

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

Terminated·—·Phase 2·NCT00003494·4 enrolled

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Terminated·—·Phase 2·NCT00003492·9 enrolled

Show 1 more trial

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Terminated·—·Phase 2·NCT00003491·17 enrolled

Breast Cancer3 trials

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Withdrawn·—·Phase 2·NCT00003455

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

Terminated·—·Phase 2·NCT00003454·19 enrolled

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Withdrawn·—·Phase 2·NCT00003536

Prostate Cancer3 trials

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Withdrawn·—·Phase 2·NCT00003517

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Terminated·—·Phase 2·NCT00003516·16 enrolled

Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer

Withdrawn·—·Phase 2·NCT00003534

35 more indications

Colon Cancer2 trials

Antineoplaston Therapy in Treating Patients With Colon Cancer

Withdrawn·—·Phase 2·NCT00003486

Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

Terminated·—·Phase 2·NCT00003485·15 enrolled

Anaplastic Astrocytoma2 trials

Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

Completed·—·Phase 2·NCT00003470·27 enrolled

Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma

Completed·—·Phase 2·NCT00003537·19 enrolled

Astrocytoma2 trials

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Terminated·—·Phase 2·NCT00003471·7 enrolled

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

Completed·—·Phase 2·NCT00003468·11 enrolled

Brain Tumors2 trials

Antineoplaston Therapy in Treating Children With Brain Tumors

Completed·—·Phase 2·NCT00003458·34 enrolled

Antineoplaston Therapy in Treating Patients With Brain Tumors

Completed·—·Phase 2·NCT00003457·40 enrolled

Stage IV2 trials

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Terminated·—·Phase 2·NCT00003453·6 enrolled

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

Terminated·—·Phase 2·NCT00003525·8 enrolled

Glioblastoma Multiforme2 trials

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

Completed·—·Phase 2·NCT00003474·40 enrolled

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

Completed·—·Phase 2·NCT00003456·40 enrolled

Primitive Neuroectodermal Tumor2 trials

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

Terminated·—·Phase 2·NCT00003515·1 enrolled

Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors

Completed·—·Phase 2·NCT00003460·13 enrolled

Malignant Brain Tumors2 trials

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

Completed·—·Phase 2·NCT00003475·40 enrolled

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Terminated·—·Phase 2·NCT00003476·8 enrolled

Central Nervous System Lymphoma1 trial

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Withdrawn·—·Phase 2·NCT00003505

Neuroendocrine Tumor1 trial

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Withdrawn·—·Phase 2·NCT00003514

Cancer of Unknown Primary1 trial

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Terminated·—·Phase 2·NCT00003526·8 enrolled

Mesothelioma1 trial

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Terminated·—·Phase 2·NCT00003508·8 enrolled

Macroglobulinemia1 trial

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Withdrawn·—·Phase 2·NCT00003512

Pancreatic Cancer1 trial

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

Terminated·—·Phase 2·NCT00003531·15 enrolled

Metastatic Prostate Cancer1 trial

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

Terminated·—·Phase 2·NCT00003533·12 enrolled

Ovarian Cancer1 trial

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Terminated·—·Phase 2·NCT00003532·7 enrolled

Ependymoma1 trial

Antineoplaston Therapy in Treating Patients With Ependymoma

Terminated·—·Phase 2·NCT00003479·9 enrolled

Soft Tissue Sarcoma1 trial

Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

Terminated·—·Phase 2·NCT00003521·14 enrolled

Kidney Cancer1 trial

Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer

Terminated·—·Phase 2·NCT00003520·15 enrolled

Neuroblastoma1 trial

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Terminated·—·Phase 2·NCT00003513·3 enrolled

Small Cell Lung Cancer1 trial

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

Terminated·—·Phase 2·NCT00003496·4 enrolled

Cancer of the Esophagus1 trial

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Terminated·—·Phase 2·NCT00003487·8 enrolled

Non-Small Cell Lung Cancer1 trial

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Terminated·—·Phase 2·NCT00003497·9 enrolled

Advanced Head and Neck Cancer1 trial

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

Terminated·—·Phase 2·NCT00003489·7 enrolled

Multiple Myeloma1 trial

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

Terminated·—·Phase 2·NCT00003511·5 enrolled

Cancer1 trial

Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine

Terminated·—·Phase 2·NCT00003522·1 enrolled

Liver Cancer1 trial

Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Terminated·—·Phase 2·NCT00003530·3 enrolled

Carcinoma1 trial

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Terminated·—·Phase 2·NCT00003452·4 enrolled

Schwannoma1 trial

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Terminated·—·Phase 2·NCT02988726·3 enrolled

Central Nervous System1 trial

Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

Terminated·—·Phase 2·NCT00003469·4 enrolled

Meningioma1 trial

Antineoplaston Therapy in Treating Patients With Meningioma

Terminated·—·Phase 2·NCT00003483·3 enrolled

Melanoma1 trial

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Terminated·—·Phase 2·NCT00003509·13 enrolled

Stomach Cancer1 trial

Antineoplaston Therapy in Treating Patients With Stomach Cancer

Terminated·—·Phase 2·NCT00003524·1 enrolled

Oligodendroglioma1 trial

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Terminated·—·Phase 2·NCT00003472·13 enrolled

Mantle Cell Lymphoma1 trial

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Withdrawn·—·Phase 2·NCT00003502

Sources

References

[1]
ClinicalTrials.gov — 61 trial records for antineoplaston A10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — antineoplaston A10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for antineoplaston A10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Burzynski Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBurzynski Research Institute

antineoplaston A10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioma4 trials

Lymphoma4 trials

Lung Cancer4 trials

Breast Cancer3 trials

Prostate Cancer3 trials

Colon Cancer2 trials

Anaplastic Astrocytoma2 trials

Astrocytoma2 trials

Brain Tumors2 trials

Stage IV2 trials

Glioblastoma Multiforme2 trials

Primitive Neuroectodermal Tumor2 trials

Malignant Brain Tumors2 trials

Central Nervous System Lymphoma1 trial

Neuroendocrine Tumor1 trial

Cancer of Unknown Primary1 trial

Mesothelioma1 trial

Macroglobulinemia1 trial

Pancreatic Cancer1 trial

Metastatic Prostate Cancer1 trial

Ovarian Cancer1 trial

Ependymoma1 trial

Soft Tissue Sarcoma1 trial

Kidney Cancer1 trial

Neuroblastoma1 trial

Small Cell Lung Cancer1 trial

Cancer of the Esophagus1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Head and Neck Cancer1 trial

Multiple Myeloma1 trial

Cancer1 trial

Liver Cancer1 trial

Carcinoma1 trial

Schwannoma1 trial

Central Nervous System1 trial

Meningioma1 trial

Melanoma1 trial

Stomach Cancer1 trial

Oligodendroglioma1 trial

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News